Aura Biosciences, Inc. (AURA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$85.6M
Cash & Equivalents
$29.9M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$708M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-07-01 | Phase3 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03941379 | A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | OTHER | Active Not Recruiting | 63 |
| NCT06007690 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatm... | PHASE3 | Recruiting | 100 |
| NCT03105102 | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease | PHASE3 | Active Not Recruiting | 1,336 |
| NCT03345823 | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Cr... | PHASE3 | Active Not Recruiting | 747 |
| NCT03006068 | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis ... | PHASE3 | Active Not Recruiting | 950 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.